Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
Apyx Medical (NASDAQ: APYX) reported second quarter 2026 revenue of $13.9 million, up 22% year over year, driven by 28% growth in the Surgical Aesthetics segment to $12.4 million, while OEM revenue declined 12% to $1.5 million. Gross margin improved to 63.9%, and net loss attributable to stockholders narrowed to $3.2 million ($0.07 per share) from $3.8 million. Adjusted EBITDA loss improved to $0.7 million from $2.0 million.
The company highlighted expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction and a limited launch of the reusable power liposuction handpiece, as well as new retrospective and cellulite/skin laxity clinical data for Renuvion and Avéli combination treatments. Apyx ended the quarter with $27.6 million in cash and cash equivalents and reaffirmed 2026 revenue guidance of $59–60 million, including $54–55 million from Surgical Aesthetics and about $5 million from OEM, while expecting 2026 operating expenses to remain below $45 million.
Positive
- Q2 2026 revenue $13.9M, up 22% year over year
- Surgical Aesthetics sales $12.4M, up 28% year over year
- Adjusted EBITDA loss improved to $0.7M from $2.0M
- Gross margin expanded to 63.9% from 62.3%
- FY 2026 revenue guidance reaffirmed at $59–60M versus $52.8M in 2025
- Cash balance $27.6M; management projects cash runway through 2027
Negative
- Net loss $3.2M in Q2 2026, or $0.07 per share
- Cash used in operations $3.5M in Q2 2026 versus $1.2M prior year
- OEM segment revenue down 12% in Q2 and guided to ~$5M for 2026 versus $7.5M in 2025
- Operating expenses rose to $10.7M from $9.7M year over year
- Long-term debt $35.3M versus total stockholders’ equity of $10.7M
News Explained
The balance sheet adds an ownership-relevant data point: common shares issued and outstanding were 42,116,330 on June 30, 2026, versus 41,785,946 on December 31, 2025; those figures do not by themselves establish why the count changed or whether existing holders were diluted.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | 1Q26 earnings | Positive | +21.9% | Revenue growth, narrower loss, improved EBITDA loss, and raised full-year guidance |
| Mar 10 | 4Q25 earnings | Positive | +0.6% | AYON launch supported revenue growth and full-year guidance increased |
| Nov 06 | 3Q25 earnings | Positive | +6.7% | Surgical Aesthetics growth, improved margins, and reduced operating losses |
| Aug 07 | 2Q25 earnings | Positive | +11.2% | Narrower loss and increased full-year guidance despite lower revenue |
| May 08 | 1Q25 earnings | Negative | -5.6% | Revenue and OEM declines outweighed improved net loss and reaffirmed guidance |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings events were generally followed by positive price reactions, with one negative reaction among the five selected events.
Key Terms
510(k) clearance regulatory
adjusted ebitda financial
gross margin financial
electrosurgical technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Reported total revenue of
$13.9 million in the second quarter of 2026 primarily driven by28% growth in the Surgical Aesthetics segment - Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026
- Reaffirmed total revenue guidance for FY2026 of
$59.0 million to$60.0 million - Management to host a conference call today at 4:30 p.m. ET
CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.
Recent Financial and Operating Highlights:
- Reported total revenue of
$13.9 million in the second quarter of 2026, compared with$11.4 million in the same period last year.- Surgical Aesthetics revenue increased to
$12.4 million in the second quarter of 2026, compared with$9.7 million in the second quarter of 2025, which was the result of sales of AYON, Renuvion generators internationally, and single-use handpieces domestically. - OEM revenue was approximately
$1.5 million in the second quarter of 2026, representing a decrease of12% from the same period last year.
- Surgical Aesthetics revenue increased to
- Net loss attributable to stockholders of
$3.2 million in the second quarter of 2026, compared with a net loss attributable to stockholders of$3.8 million in the second quarter of 2025. - Adjusted EBITDA loss was
$0.7 million for the second quarter of 2026, compared with an Adjusted EBITDA loss of$2.0 million for the second quarter of 2025. - Received expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction and commenced a limited commercial launch of the reusable power liposuction handpiece with targeted early adopters.
- Published retrospective clinical data demonstrating that Renuvion used in combination with liposuction was associated with significantly higher patient satisfaction, lower abdominoplasty and revision rates and comparable complication rates versus liposuction alone.
- Reported positive clinical data demonstrating significant improvements in cellulite appearance and skin laxity following a single-session combination treatment utilizing Avéli and Renuvion.
- Showcased Renuvion and the AYON Body Contouring System at Miami Swim Week through the Body by Apyx event, highlighting real patient transformations and increasing awareness among consumers and aesthetic providers.
“We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported
The following tables present revenue by reportable segment and geography:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||
| (In thousands) | 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||||||||||||||
| Sales by Reportable Segment | ||||||||||||||||||||||||
| Surgical Aesthetics | $ | 12,386 | $ | 9,670 | 28.1 | % | $ | 23,120 | $ | 17,557 | 31.7 | % | ||||||||||||
| OEM | 1,498 | 1,703 | (12.0 | )% | 3,254 | 3,246 | 0.2 | % | ||||||||||||||||
| Total | $ | 13,884 | $ | 11,373 | 22.1 | % | $ | 26,374 | $ | 20,803 | 26.8 | % | ||||||||||||
| Sales by Domestic and International | ||||||||||||||||||||||||
| Domestic | $ | 9,408 | $ | 7,776 | 21.0 | % | $ | 17,520 | $ | 14,519 | 20.7 | % | ||||||||||||
| International | 4,476 | 3,597 | 24.4 | % | 8,854 | 6,284 | 40.9 | % | ||||||||||||||||
| Total | $ | 13,884 | $ | 11,373 | 22.1 | % | $ | 26,374 | $ | 20,803 | 26.8 | % | ||||||||||||
Second Quarter 2026 Results:
Total revenue for the three months ended June 30, 2026 increased
Gross profit for the three months ended June 30, 2026, increased
Operating expenses increased to
Other expense, net was relatively flat at
Net loss attributable to stockholders was
Adjusted EBITDA loss for the three months ended June 30, 2026 was
For the three months ended June 30, 2026, net cash used in operating activities was
As of June 30, 2026, the Company had cash and cash equivalents of
Financial Guidance for Full Year 2026:
The Company reaffirmed its financial guidance targets for the year ending December 31, 2026:
- Total revenue in the range of
$59.0 million to$60.0 million , compared with$52.8 million reported for the year ended December 31, 2025.- Total revenue guidance assumes:
- Surgical Aesthetics revenue is expected to be in the range of
$54.0 million to$55.0 million , compared with approximately$45.3 million reported for the year ended December 31, 2025. - OEM revenue is expected to be approximately
$5.0 million , compared with approximately$7.5 million for the year ended December 31, 2025.
- Surgical Aesthetics revenue is expected to be in the range of
- Total revenue guidance assumes:
- The Company continues to expect operating expenses of less than
$45.0 million for the year ended December 31, 2026.
Conference Call Details:
Management will host a conference call at 4:30 p.m. Eastern Time today, August 6th, to discuss the results of the second quarter ended June 30, 2026, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 53282. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.
An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website (click here).
Investor Relations Contact:
Jeremy Feffer, Managing Director, LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About AYON Body Contouring System™:
AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products including its Helium Plasma Platform Technology products marketed and sold as Renuvion®, the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is anFDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Sales, net | $ | 13,884 | $ | 11,373 | $ | 26,374 | $ | 20,803 | ||||||||
| Cost of sales | 5,014 | 4,290 | 9,579 | 8,055 | ||||||||||||
| Gross profit | 8,870 | 7,083 | 16,795 | 12,748 | ||||||||||||
| Other costs and expenses: | ||||||||||||||||
| Research and development | 793 | 824 | 1,558 | 1,628 | ||||||||||||
| Professional services | 1,224 | 1,496 | 2,466 | 2,861 | ||||||||||||
| Salaries and related costs | 3,374 | 3,072 | 6,627 | 6,153 | ||||||||||||
| Selling, general and administrative | 5,285 | 4,265 | 8,861 | 7,731 | ||||||||||||
| Total other costs and expenses | 10,676 | 9,657 | 19,512 | 18,373 | ||||||||||||
| Loss from operations | (1,806 | ) | (2,574 | ) | (2,717 | ) | (5,625 | ) | ||||||||
| Interest income | 250 | 278 | 494 | 582 | ||||||||||||
| Interest expense | (1,394 | ) | (1,393 | ) | (2,763 | ) | (2,769 | ) | ||||||||
| Other income, net | 2 | — | 38 | — | ||||||||||||
| Total other expense, net | (1,142 | ) | (1,115 | ) | (2,231 | ) | (2,187 | ) | ||||||||
| Loss before income taxes | (2,948 | ) | (3,689 | ) | (4,948 | ) | (7,812 | ) | ||||||||
| Income tax expense | 124 | 49 | 267 | 98 | ||||||||||||
| Net loss | (3,072 | ) | (3,738 | ) | (5,215 | ) | (7,910 | ) | ||||||||
| Net loss attributable to non-controlling interest | 171 | 40 | 136 | 18 | ||||||||||||
| Net loss attributable to stockholders | $ | (3,243 | ) | $ | (3,778 | ) | $ | (5,351 | ) | $ | (7,928 | ) | ||||
| Loss per share: | ||||||||||||||||
| Basic and diluted | $ | (0.07 | ) | $ | (0.09 | ) | $ | (0.12 | ) | $ | (0.19 | ) | ||||
| APYX MEDICAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) | |||||||
| June 30, 2026 | December 31, 2025 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 27,617 | $ | 31,740 | |||
| Trade accounts receivable, net of allowance of | 13,614 | 16,776 | |||||
| Inventories, net of provision for obsolescence of | 10,747 | 8,602 | |||||
| Prepaid expenses and other current assets | 1,177 | 1,353 | |||||
| Total current assets | 53,155 | 58,471 | |||||
| Property and equipment, net of accumulated depreciation and amortization of | 2,110 | 2,371 | |||||
| Operating lease right-of-use assets | 4,014 | 4,218 | |||||
| Finance lease right-of-use assets | 17 | 28 | |||||
| Other assets | 1,776 | 1,752 | |||||
| Total assets | $ | 61,072 | $ | 66,840 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 2,190 | $ | 3,058 | |||
| Accrued expenses and other current liabilities | 6,692 | 8,214 | |||||
| Current portion of operating lease liabilities | 451 | 407 | |||||
| Current portion of finance lease liabilities | 21 | 21 | |||||
| Total current liabilities | 9,354 | 11,700 | |||||
| Long-term debt, net of debt discounts and issuance costs | 35,328 | 34,849 | |||||
| Long-term operating lease liabilities | 3,828 | 4,051 | |||||
| Long-term finance lease liabilities | 2 | 12 | |||||
| Long-term contract liabilities | 1,134 | 1,050 | |||||
| Other liabilities | 336 | 347 | |||||
| Total liabilities | 49,982 | 52,009 | |||||
| EQUITY | |||||||
| Preferred stock, | — | — | |||||
| Common stock, | 42 | 42 | |||||
| Additional paid-in capital | 105,094 | 103,620 | |||||
| Accumulated deficit | (94,473 | ) | (89,122 | ) | |||
| Total stockholders’ equity | 10,663 | 14,540 | |||||
| Non-controlling interest | 427 | 291 | |||||
| Total equity | 11,090 | 14,831 | |||||
| Total liabilities and equity | $ | 61,072 | $ | 66,840 | |||
Use of Non-GAAP Financial Measure:
The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net loss attributable to stockholders (GAAP) plus income tax expense (benefit), interest income and expense, depreciation and amortization, stock-based compensation expense and other significant non-recurring items.
We present the following non-GAAP measure of adjusted EBITDA because we believe such measure is a useful indicator of our operating performance. Our management uses adjusted EBITDA principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.
| APYX MEDICAL CORPORATION RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA (Unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| (In thousands) | June 30, | June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net loss attributable to stockholders | $ | (3,243 | ) | $ | (3,778 | ) | $ | (5,351 | ) | $ | (7,928 | ) | ||||
| Interest income | (250 | ) | (278 | ) | (494 | ) | (582 | ) | ||||||||
| Interest expense | 1,394 | 1,393 | 2,763 | 2,769 | ||||||||||||
| Income tax expense | 124 | 49 | 267 | 98 | ||||||||||||
| Depreciation and amortization | 196 | 132 | 398 | 270 | ||||||||||||
| Stock based compensation | 1,074 | 520 | 1,386 | 971 | ||||||||||||
| Adjusted EBITDA | $ | (705 | ) | $ | (1,962 | ) | $ | (1,031 | ) | $ | (4,402 | ) | ||||
